Answers are grounded in this paper and cite their sources.
In this commentary, we discuss the investigation into reports of T-cell malignancies following chimeric antigen receptor T-cell therapy. We argue that although these cases should be thoroughly examined, current data suggest that such risks with autologous chimeric antigen receptor T cells are remarkably low compared with other cancer treatments. We also emphasize the importance of continued research, transparent reporting, and participation in postauthorization safety studies.
No takes yet. Share an insight, caveat, or question.
Ruella et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: